Key Highlights

  • Adial Pharmaceuticals shares finished the session up 25% at $4.99.
  • The company finalized its Acquisition of Azora Therapeutics.
  • The deal pivots strategic priority toward AT177, a colon-targeted oral AhR agonist for ulcerative colitis.
  • Adial secured the initial $32 million of a potential $64 million financing round.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares finished the session up 25% at $4.99 after the company finalized its acquisition of Azora Therapeutics, pivoting its strategic priority toward AT177, a colon-targeted oral AhR agonist for ulcerative colitis.

What Happened

Alongside the acquisition, Adial secured the initial $32 million of a potential $64 million financing round. The company reported a widened Q2 net loss of $52.0 million, primarily due to a $46.2 million non-cash IPR&D charge tied to the acquisition.

Adial's bolstered $28.7 million cash reserves provide an operational runway through the second half of 2027.

Market Reaction

Shares rose sharply as investors responded to the strategic pivot toward AT177 and the extended cash runway, appearing to look past the widened net loss given its non-cash, acquisition-related nature.

Outlook

Continued clinical advancement of AT177 in ulcerative colitis, supported by the extended runway into the second half of 2027, is likely to remain the key Factor shaping sentiment toward Adial Pharmaceuticals' stock going forward.